Last updated on June 2019

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C) ROS1 or ALK Gene Rearrangements (Fusions)


Brief description of study

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Clinical Study Identifier: NCT02568267

Find a site near you

Start Over

Yale University

New Haven, CT United States
  Connect »

Karmanos Cancer Center

Detroit, MI United States
  Connect »

Levine Cancer Institute

Charlotte, NC United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Flinders Medical Centre

Bedford Park, Australia
  Connect »

Austin Hospital

Heidelberg, Australia
  Connect »

Liverpool Hospital

Liverpool, Australia
  Connect »

Newcastle Private Hospital

New Lambton Heights, Australia
  Connect »

Mayo Clinic

Scottsdale, AZ United States
  Connect »

Scripps Clinic

La Jolla, CA United States
  Connect »

UCSF Mount Zion Medical Ctr

San Francisco, CA United States
  Connect »

Sarcoma Oncology Center

Santa Monica, CA United States
  Connect »

Cleveland Clinic Florida

Weston, FL United States
  Connect »

Northwestern University

Chicago, IL United States
  Connect »

Henry Ford Hospital

Detroit, MI United States
  Connect »

North Shore Hem Onc Associates

East Setauket, NY United States
  Connect »

Duke Cancer Institute

Durham, NC United States
  Connect »

OSU, James Cancer Hospital

Columbus, OH United States
  Connect »

Asan Medical Center.

Seoul, Korea, Republic of
  Connect »

Winship Cancer Institute

Atlanta, GA United States
  Connect »

Washington University

Saint Louis, MO United States
  Connect »

Oregon Health & Science Univ

Portland, OR United States
  Connect »

Samsung Medical Center

Seoul, Korea, Republic of
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.